<DOC>
	<DOCNO>NCT00905684</DOCNO>
	<brief_summary>This study prospective , company-sponsored , non-interventional cohort study 5000 patient European country country Middle East newly prescribe available OC . Patients follow approximately 6 month initial visit . Selection Study Population : Women enrol decision treatment Yasmin OC make . Physicians consult full prescribing information respective OC enrol patient familiarize safety information product package label .</brief_summary>
	<brief_title>Effects Counseling Continuation Rates Compliance Newly Prescribed Oral Contraceptives ( YasminÂ® Any Other Oral Contraceptives ( OC )</brief_title>
	<detailed_description />
	<mesh_term>Contraceptives , Oral</mesh_term>
	<mesh_term>Drospirenone ethinyl estradiol combination</mesh_term>
	<mesh_term>Contraceptive Agents</mesh_term>
	<criteria>Women find eligible OC use newly prescribe OC accordance term respective marketing authorization Starter ( firstever user OC ) switcher another OC ( incl . woman history OC use ) The contraindication warning Summary Product Characteristics must follow .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>Compliance</keyword>
	<keyword>Hormonal Contraception</keyword>
</DOC>